Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.06B 10.51B 9.9B 9.02B 16.91B 1,155B 16.93B 119B 45.71B 589B 45.3B 44.3B 1,899B P/E 2026 *
-82.7x
P/E 2027 * 82.9x
Enterprise Value 11.53B 10.06B 9.47B 8.63B 16.17B 1,105B 16.19B 113B 43.72B 563B 43.33B 42.37B 1,817B EV / Sales 2026 *
7.56x
EV / Sales 2027 * 5.18x
Free-Float
94.17%
Yield 2026 *
-
Yield 2027 * -
1 day-0.18%
1 week-0.57%
Current month-3.66%
1 month+1.62%
3 months+1.44%
6 months+16.21%
Current year-10.66%
1 week 515.98
Extreme 515.98
539.29
1 month 506.29
Extreme 506.29
552.08
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 11.25
Extreme 11.25
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap. Importance
11/9/26 Sell

Chief Executive Officer

-5,221 0.0226%
17/8/26 Sell

General Counsel

-664 0.0029%
15/8/26 Free

Director

1,725 0.0075%
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%-0.57%+18.23%+239.30% 12.06B
+4.98%+5.73%+54.45%+113.83% 74.33B
-1.54%-0.49%+35.39%+79.01% 62.26B
-0.66%+7.14%+39.36%+29.20% 27.72B
-0.84%+0.31%-17.06%+359.65% 26.42B
+4.21%+5.34%+3.18%-2.66% 24.62B
+0.84%+6.00%+25.53%-9.89% 20.72B
+0.87%-2.52%+151.81%+328.17% 15.01B
+2.73%+3.16%+48.31%+173.28% 14.18B
+2.60%-1.49%-10.26%+816.58% 13.48B
Average +1.28%+0.41%+34.89%+212.65% 29.08B
Weighted average by Cap. +1.49%+2.07%+36.26%+153.71%

Financials

2026 *2027 *
Net sales 1.53B 1.33B 1.25B 1.14B 2.14B 146B 2.14B 15.01B 5.79B 74.49B 5.73B 5.61B 240B 2.14B 1.87B 1.76B 1.6B 3.01B 205B 3.01B 21.09B 8.13B 105B 8.06B 7.88B 338B
Net income -184M -160M -151M -138M -258M -17.61B -258M -1.81B -697M -8.97B -691M -675M -28.96B 200M 174M 164M 150M 280M 19.16B 281M 1.97B 758M 9.76B 751M 735M 31.5B
Net Debt -525M -457M -431M -392M -735M -50.25B -736M -5.16B -1.99B -25.6B -1.97B -1.93B -82.6B -943M -822M -775M -705M -1.32B -90.36B -1.32B -9.28B -3.58B -46.03B -3.54B -3.46B -149B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
23/09/26 USD 520.28 -0.32% 32,546
21/09/26 USD 521.96 -1.80% 186,148
18/09/26 USD 531.52 -0.54% 330,617
17/09/26 USD 534.40 +1.00% 153,313
16/09/26 USD 529.09 +1.11% 298,474
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
521.96USD
Average target price
678.06USD
Spread / Average Target
+29.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!